New HIV drug shows promise in small trial for Drug-Resistant patients
NCT ID NCT03902522
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This trial tested an injectable drug called PRO 140 (Leronlimab) in 6 people with HIV who had developed resistance to standard medications. The goal was to see if adding PRO 140 to their current failing therapy could reduce the amount of virus in their blood. The study lasted 25 weeks and also looked at safety and tolerability.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PRO 140 (Leronlimab) - an injectable drug that blocks HIV from entering cells
What this could lead to
If successful, this could provide a new treatment option for people with HIV who have developed resistance to standard antiretroviral drugs.
What could go wrong
This is a very small early-phase trial with only 6 participants, so results may not apply broadly. The drug is tested alongside failing therapy, and long-term safety and efficacy are not yet established.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CD02_OpenLabel Investigational Site
Palm Springs, California, 92262, United States
-
CD02_OpenLabel Investigational Site
San Francisco, California, 94115, United States
-
CD02_OpenLabel Investigational Site
New Haven, Connecticut, 06510, United States
-
CD02_OpenLabel Investigational Site
Ft. Pierce, Florida, 34982, United States
-
CD02_OpenLabel Investigational Site
Miami, Florida, 33136, United States
-
CD02_OpenLabel Investigational Site
Miami, Florida, 33139, United States
-
CD02_OpenLabel Investigational Site
Miami, Florida, 33169, United States
-
CD02_OpenLabel Investigational Site
Orlando, Florida, 32803, United States
-
CD02_OpenLabel Investigational Site
West Palm Beach, Florida, 33401, United States
-
CD02_OpenLabel Investigational Site
Decatur, Georgia, 30033, United States
-
CD02_OpenLabel Investigational Site
Chicago, Illinois, 60613, United States
-
CD02_OpenLabel Investigational Site
Wichita, Kansas, 67214, United States
-
CD02_OpenLabel Investigational Site
Syracuse, New York, 13210, United States
-
CD02_OpenLabel Investigational Site
Bellaire, Texas, 77301, United States
-
CD02_OpenLabel Investigational Site
Houston, Texas, 77004, United States
-
CD02_OpenLabel Investigational Site
Houston, Texas, 77098, United States
-
CD02_OpenLabel Investigational Site
Spokane, Washington, 99202, United States